Trimethoprim/Sulfamethoxazole

ApprovedSmall molecule

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Trimethoprim/Sulfamethoxazole is one of 212 small molecule programs targeting Abscess. It is currently in Approved.

Indications

Total Trials

Active Trials

211

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

Rheumatic DiseaseActive, not recruiting

Recurrent Urinary Tract InfectionsActive, not recruiting

Liver AbscessActive, not recruiting

Atopic DermatitisActive, not recruiting

Cystic FibrosisActive, not recruiting

TuberculosisActive, not recruiting

EczemaRecruiting

Urinary Tract InfectionActive, not recruiting

AbscessPhase 3

Active, not recruiting

Rheumatic DiseaseApproved

Active, not recruiting

Recurrent Urinary Tract InfectionsPhase 3

Active, not recruiting

Liver AbscessApproved

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

TuberculosisPhase 2/Phase 3

Active, not recruiting

EczemaPhase 2

Recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Trimethoprim/Sulfamethoxazole

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

19 2

Fludara

Sanofi

Phase 3

1 3

Ciclosporin

Novartis

Phase 3

4 4

Rocatinlimab

Amgen

Phase 3

8 5

GR1802

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 3

1 6

SHR-1819

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

4 7

Fucidin

LEO Pharma

Phase 3

1 8

EBGLYSS

Eli Lilly

Preclinical

23 9

Cibinqo

Pfizer

Preclinical

11 10

Prograf

VVeloxis Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Posterior Urethral Valve

NCT06737016

Post-ApprovalRecruiting

Rheumatic Disease

NCT06499233

Q1 2027

Phase 2Recruiting

Eczema

NCT01631617

Clinical

Trials by Indication[1]

Urinary Tract Infection2 trials

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01595529·717 enrolled

Probiotics for Girls With Recurring Urinary Tract Infections

Withdrawn·—·Phase 2·NCT00789464

Antibiotic Prophylaxis2 trials

Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole

Unknown status·UUmeå University·Phase 2·NCT02734732·2,800 enrolled

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

Completed·UUniversity of California, San Diego·N/A·NCT02944825·80 enrolled

Prophylaxis2 trials

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

Completed·RRadboud University Medical Center·Phase 4·NCT03228108·1,538 enrolled

Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT01747278·80 enrolled

Abscess2 trials

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

Completed·—·Phase 3·NCT00691600·23 enrolled

Antibiotic Therapy After Incision and Drainage for Abscess

Withdrawn·WWake Forest University·N/A·NCT00900510

Recurrent urinary tract infections1 trial

D Mannose in Recurrent Urinary Tract Infections

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 3·NCT01808755·60 enrolled

10 more indications

Rheumatic Disease1 trial

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Recruiting·TTongji Hospital·Phase 4·NCT06499233·800 enrolled

Cystic Fibrosis1 trial

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01349192·47 enrolled

Congenital Abnormalities1 trial

Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract

Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 3·NCT02021006·292 enrolled

Liver abscess1 trial

Antibiotics for Klebsiella Liver Abscess Study

Completed·NNational University Hospital, Singapore·Phase 4·NCT01723150·152 enrolled

Recruiting·MMansoura University·Phase 3·NCT06737016·50 enrolled

Tuberculosis1 trial

Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV

Terminated·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 2/3·NCT00080119·1,354 enrolled

Staphylococcus Aureus1 trial

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

Completed·JJohns Hopkins University·Phase 2·NCT01594827·29 enrolled

Eczema1 trial

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Recruiting·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT01631617·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Trimethoprim/Sulfamethoxazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimethoprim/Sulfamethoxazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimethoprim/Sulfamethoxazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Trimethoprim/Sulfamethoxazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Urinary Tract Infection2 trials

Antibiotic Prophylaxis2 trials

Prophylaxis2 trials

Abscess2 trials

Recurrent urinary tract infections1 trial

Rheumatic Disease1 trial

Cystic Fibrosis1 trial

Congenital Abnormalities1 trial

Liver abscess1 trial

Islet Transplantation1 trial

Plasmodium Falciparum1 trial

Posterior Urethral Valve1 trial

Tuberculosis1 trial

Staphylococcus Aureus1 trial

Eczema1 trial

References

Drug Info

Quick Facts

Related News